Table 2.

LOD scores from the two-point variance component linkage analysis^*

chr	Marker	Cytogenetic Location	cM	Probable & Possible		Probable only
				APOE Unadjusted	APOE ε4+	APOE Unadjusted	APOE ε4+
1	TATC028	1q24	184.6	1.84	1.56	1.61	1.36
2	D2S1394	2p13	90.8	1.53	1.18	1.42	1.43
2	D2S1328	2q14	132.6			1.57	1.28
2	D2S1391	2q32	186.2	1.36	1.22
3	D3S1768	3p22	62	1.43	1.04	1.23	1.07
4	GATA70E01	4p15	35	1.79	1.76	1.39	1.28
5	D5S1501	5q14	85	1.06	1.17	1.33	1.69
5	D5S1462	5q15	105	1.80	2.38	2.72	3.11
5	D5S2501	5q22	117	1.55	1.35	1.95	2.18
5	D5S1480	5q32	147.0			1.05	1.07
6	ATTT030	6p24	17.9			0.84	1.03
6	GATA184A08	6q24	146.0			0.99	1.23
7	GATA104	7q35	155.0			1.55	1.24
7	D7S3070	7q36	163	1.85	1.36	2.07	1.57
7	D7S3058	7q36	174	1.38	1.18	1.87	1.67
7	MFD442GTTT002	7q36	178.6	1.95	2.70	1.77	2.29
13	D13S787	13q12	9.0			1.30	1.26
14	D14S617	14q32	106	2.25	2.46	2.60	2.36
16	TTAT023Z	16p12	38.4			1.25	1.27
16	D16S3253	16q12	72	1.60	1.04
16	AAT107	16q21	81.1			1.08	1.04
17	G10693	17p13	14.7	1.67	1.49
17	D17S1301	17q25	100	2.63	2.58	2.71	2.94
17	AAT095	17q26	119.5			1.27	1.05
18	D18S542	18p11	41	1.87	1.55	1.36	1.43
21	D21S1446	21q22	57.8	0.82	1.08

^*Individuals with probable AD and probable or possible AD were considered affected. Only markers with LOD score above threshold of 1 are shown.